News Releases

Date Title
01/31/2014 Summary ToggleEnanta Pharmaceuticals Announces Results from Four All-Oral, Interferon-Free, Phase 3 Studies for the Treatment of Genotype 1 Hepatitis C Virus Infection
01/13/2014 Summary ToggleEnanta Pharmaceuticals Initiates Phase 1 Study of MRSA Infection Candidate EDP-788
01/06/2014 Summary ToggleEnanta Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
12/10/2013 Summary ToggleEnanta Pharmaceuticals Announces 96 Percent SVR12 in Treatment Experienced Genotype 1 Hepatitis C Patients in SAPPHIRE-II Study
11/25/2013 Summary ToggleEnanta Pharmaceuticals to Present at the Deutsche Bank 2013 BioFest
11/25/2013 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for the Fiscal Fourth Quarter and Year Ended September 30, 2013
11/25/2013 Summary ToggleEnanta Pharmaceuticals Announces the Appointment of Bruce L.A. Carter, Ph.D. to Board of Directors
11/18/2013 Summary ToggleEnanta Pharmaceuticals Announces 96 Percent SVR12 in SAPPHIRE-I Study
11/15/2013 Summary ToggleEnanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Fourth Quarter and Year Ended September 30, 2013
11/06/2013 Summary ToggleEnanta Pharmaceuticals to Present at the 2013 Credit Suisse Healthcare Conference